The results of a previous study showed that the use of SGK1 inhibitors, including GSK650394 and EMD638683, significantly reduced the size of the cerebral infarct, with GSK650394 providing greater improvement in infarct area (14). This evidence concerns the gene SGK1 and cerebral infarction.